Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D02XDG
|
|||
Drug Name |
PMID26560530-Compound-3
|
|||
Drug Type |
Small molecular drug
|
|||
Company |
Merck & Co., Inc
|
|||
Structure |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Tissue transglutaminase (TG2) | Target Info | Inhibitor | [1] |
Target's Patent Info | Tissue transglutaminase (TG2) | Target's Patent Info | [1] | |
KEGG Pathway | Huntington's disease | |||
Pathway Interaction Database | Beta1 integrin cell surface interactions | |||
Thromboxane A2 receptor signaling | ||||
Alpha9 beta1 integrin signaling events |
References | Top | |||
---|---|---|---|---|
REF 1 | Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.